These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 18758226

  • 1. Relationship between glucocorticoid receptor signal pathway and androgen-independent prostate cancer.
    Yan TZ, Jin FS, Xie LP, Li LC.
    Urol Int; 2008; 81(2):228-33. PubMed ID: 18758226
    [Abstract] [Full Text] [Related]

  • 2. Novel steroid receptor phyto-modulator compound a inhibits growth and survival of prostate cancer cells.
    Yemelyanov A, Czwornog J, Gera L, Joshi S, Chatterton RT, Budunova I.
    Cancer Res; 2008 Jun 15; 68(12):4763-73. PubMed ID: 18559523
    [Abstract] [Full Text] [Related]

  • 3. Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts.
    Chiu FL, Lin JK.
    Prostate; 2008 Jan 01; 68(1):61-71. PubMed ID: 18008333
    [Abstract] [Full Text] [Related]

  • 4. Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation.
    Seaton A, Scullin P, Maxwell PJ, Wilson C, Pettigrew J, Gallagher R, O'Sullivan JM, Johnston PG, Waugh DJ.
    Carcinogenesis; 2008 Jun 01; 29(6):1148-56. PubMed ID: 18487223
    [Abstract] [Full Text] [Related]

  • 5. Interleukin-6 undergoes transition from growth inhibitor associated with neuroendocrine differentiation to stimulator accompanied by androgen receptor activation during LNCaP prostate cancer cell progression.
    Lee SO, Chun JY, Nadiminty N, Lou W, Gao AC.
    Prostate; 2007 May 15; 67(7):764-73. PubMed ID: 17373716
    [Abstract] [Full Text] [Related]

  • 6. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO, Pinder E, Chun JY, Lou W, Sun M, Gao AC.
    Prostate; 2008 Jan 01; 68(1):85-91. PubMed ID: 18008330
    [Abstract] [Full Text] [Related]

  • 7. [Induction of apoptosis by mifepristone in androgen-independent prostate cancer cell lines in vitro].
    Zhang H, Lü JJ, Gao QZ, Zhang J.
    Zhonghua Wai Ke Za Zhi; 2006 Mar 15; 44(6):382-5. PubMed ID: 16638347
    [Abstract] [Full Text] [Related]

  • 8. Regulation of androgen receptor transactivity and mTOR-S6 kinase pathway by Rheb in prostate cancer cell proliferation.
    Kobayashi T, Shimizu Y, Terada N, Yamasaki T, Nakamura E, Toda Y, Nishiyama H, Kamoto T, Ogawa O, Inoue T.
    Prostate; 2010 Jun 01; 70(8):866-74. PubMed ID: 20127734
    [Abstract] [Full Text] [Related]

  • 9. Role of coordinated molecular alterations in the development of androgen-independent prostate cancer: an in vitro model that corroborates clinical observations.
    Shi Y, Chatterjee SJ, Brands FH, Shi SR, Pootrakul L, Taylor CR, Datar R, Cote RJ.
    BJU Int; 2006 Jan 01; 97(1):170-8. PubMed ID: 16336351
    [Abstract] [Full Text] [Related]

  • 10. Dexamethasone suppresses DU145 cell proliferation and cell cycle through inhibition of the extracellular signal-regulated kinase 1/2 pathway and cyclin D1 expression.
    Gao QZ, Lu JJ, Liu ZD, Zhang H, Wang SM, Xu H.
    Asian J Androl; 2008 Jul 01; 10(4):635-41. PubMed ID: 18097517
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Ubiquitous mitochondrial creatine kinase is overexpressed in the conditioned medium and the extract of LNCaP lineaged androgen independent cell lines and facilitates prostate cancer progression.
    Pang B, Zhang H, Wang J, Chen WZ, Li SH, Shi QG, Liang RX, Xie BX, Wu RQ, Qian XL, Yu L, Li QM, Huang CF, Zhou JG.
    Prostate; 2009 Aug 01; 69(11):1176-87. PubMed ID: 19415690
    [Abstract] [Full Text] [Related]

  • 14. Chronic azacitidine treatment results in differentiating effects, sensitizes against bicalutamide in androgen-independent prostate cancer cells.
    Gravina GL, Festuccia C, Millimaggi D, Dolo V, Tombolini V, de Vito M, Vicentini C, Bologna M.
    Prostate; 2008 May 15; 68(7):793-801. PubMed ID: 18324645
    [Abstract] [Full Text] [Related]

  • 15. Interleukin-6 stimulation of growth of prostate cancer in vitro and in vivo through activation of the androgen receptor.
    Malinowska K, Neuwirt H, Cavarretta IT, Bektic J, Steiner H, Dietrich H, Moser PL, Fuchs D, Hobisch A, Culig Z.
    Endocr Relat Cancer; 2009 Mar 15; 16(1):155-69. PubMed ID: 19011039
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Expression of PIAS3 an inhibitor of activated STAT3 protein in human prostate cancer].
    Gan L, Yin ZF, Li M.
    Zhonghua Yi Xue Za Zhi; 2008 Feb 05; 88(6):419-21. PubMed ID: 18581899
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Interleukin-6 protects LNCaP cells from apoptosis induced by androgen deprivation through the Stat3 pathway.
    Lee SO, Lou W, Johnson CS, Trump DL, Gao AC.
    Prostate; 2004 Aug 01; 60(3):178-86. PubMed ID: 15176047
    [Abstract] [Full Text] [Related]

  • 20. Interleukin-6 regulation of prostate cancer cell growth.
    Culig Z, Steiner H, Bartsch G, Hobisch A.
    J Cell Biochem; 2005 Jun 01; 95(3):497-505. PubMed ID: 15838876
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.